In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), ...

An FDA approval later this year for Arrowhead’s plozasiran in FCS would put it in direct competition with Ionis’ Tryngolza.

The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP's Annual MLK Jr.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

ManaMed LLC, a global leader in orthopedic mobility and post-operative rehabilitation equipment, is thrilled to announce the launch of three groundbreaking products designed to enhance patient care.

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Arrowhead Pharmaceuticals announces FDA acceptance of NDA for plozasiran to treat familial chylomicronemia syndrome, with a target action date of Nov.

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...